Focused On-demand Library for WD repeat domain phosphoinositide-interacting protein 2

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.

Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.

The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.

We use our state-of-the-art dedicated workflow for designing focused libraries.

 Fig. 1. The sreening workflow of Receptor.AI

Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.

Our library distinguishes itself through several key aspects:

  • The Receptor.AI platform integrates all available data about the target protein, including past experiments, literature data, known ligands, structural information and more. This consolidated approach maximises the probability of prioritising highly relevant compounds.
  • The platform uses sophisticated molecular simulations to identify possible binding sites so that the compounds in the focused library are suitable for discovering allosteric inhibitors and the binders for cryptic pockets.
  • The platform integrates over 50 highly customisable AI models, which are thoroughly tested and validated on a multitude of commercial drug discovery programs and research projects. It is designed to be efficient, reliable and accurate. All this power is utilised when producing the focused libraries.
  • In addition to producing the focused libraries, Receptor.AI provides services and end-to-end solutions at every stage of preclinical drug discovery. The pricing model is success-based, which reduces your risks and leverages the mutual benefits of the project's success.







Alternative names:

WIPI49-like protein 2

Alternative UPACC:

Q9Y4P8; B3KNC2; Q5MNZ8; Q6FI96; Q75L50; Q96IE4; Q9Y364


WD repeat domain phosphoinositide-interacting protein 2 (WIPI2) is pivotal in autophagy, aiding in the degradation of cytoplasmic materials via autophagosomes to lysosomes. It plays a crucial role in the early formation of preautophagosomal structures, activated by phosphatidylinositide 3-phosphate on the endoplasmic reticulum. WIPI2 facilitates the recruitment of the ATG12-ATG5-ATG16L1 complex, essential for autophagosomal membrane elongation and pathogen clearance, including bacteria like Salmonella.

Therapeutic significance:

WIPI2's involvement in intellectual developmental disorder with short stature and variable skeletal anomalies highlights its potential as a therapeutic target. Understanding the role of WIPI2 could open doors to potential therapeutic strategies for treating this genetic disorder and enhancing autophagy-related therapies.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.